Adding targeted radiation to standard lung cancer treatment

Plain-English translation of NCT06141070 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing whether combining radiation therapy with standard chemotherapy and immunotherapy works better than chemotherapy and immunotherapy alone for people with advanced non-small cell lung cancer that has spread to 5 or fewer locations in the body. About half of patients will receive the standard treatment, and half will receive the standard treatment plus targeted radiation aimed at all visible cancer sites. The goal is to see if adding radiation helps people live longer and stay cancer-free longer.

When lung cancer spreads to only a few distant sites, doctors wonder if treating those specific spots with focused radiation — in addition to standard chemotherapy and immunotherapy — might improve outcomes. This trial will provide clear evidence about whether this combined approach is better than chemotherapy and immunotherapy alone.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced non-small cell lung cancer that has spread to 5 or fewer locations outside the lungs and lymph nodes
your cancer has not been treated with chemotherapy or radiation before (though previous adjuvant therapy is allowed)
you are physically fit enough to receive standard first-line chemotherapy, immunotherapy, or a combination of both
you are 18 years or older with no upper age limit
you have adequate organ and bone marrow function as determined by blood tests

You likely don't qualify if…

you have only a single brain tumor or a single tumor in the opposite lung as your only distant cancer spread
you have cancer cells in your lung fluid, abdominal fluid, or fluid around your brain
you have a genetic mutation (such as EGFR, ALK, or ROS1) that requires a targeted therapy instead of chemotherapy or immunotherapy
you have severe lung scarring (pulmonary fibrosis) that would make the planned treatment unsafe
you are pregnant, breastfeeding, or unwilling to use effective birth control during treatment and for 90 days after

What participation looks like

If you join this trial, you'll be randomly assigned to receive either standard chemotherapy and immunotherapy alone, or the same treatment plus radiation therapy to all known cancer sites. The radiation would be delivered during the first three months of treatment, ideally starting around your second cycle of chemotherapy. You'll visit the clinic regularly for treatment and monitoring, with imaging scans every three months to check how you're responding. The study will track you over time to see how long you survive and how well the treatment controls your cancer.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Adding targeted radiation to standard lung cancer treatment

What is this trial?

Do you qualify?

What participation looks like

Trial locations